A5050333645- Ferroptosis and cancer prognosis
- RNA modifications and cancer
- RNA Research and Splicing
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Kruppel-like factors research
- Cancer-related gene regulation
- Immune cells in cancer
- Epigenetics and DNA Methylation
- Chronic Myeloid Leukemia Treatments
Suizhou Central Hospital
2024
Shanghai Pulmonary Hospital
2022-2024
Tongji University
2022-2024
The First Affiliated Hospital, Sun Yat-sen University
2023
Fudan University
2023
Sun Yat-sen University
2023
Zhongshan Hospital
2023
Fudan University Shanghai Cancer Center
2022
Shanghai International Medical Center
2022
Mitochondrial ribosomal protein S23 (MRPS23), a component of the ribosome small subunit, has been reported to be overexpressed in various cancers and predicted involved increased cell proliferation. It confirmed that MRPS23 was regulation breast cancer hepatocellular carcinoma However, little is known about function glioma. In this study, we found expression higher gliomas than adjacent normal tissues. Higher correlated with poorer prognosis, unfavorable histological features, absence...
Abstract Background Zinc finger and bric-a-brac/tramtrack/broad (ZBTB) domain-containing proteins have been reported to be associated with many tumors’ development. However, in tumor initiation progression, the role of ZBTB9, one protein family, its prognostic value were yet elucidated Liver Hepatocellular Carcinoma (LIHC). Methods We used R software online bioinformatics analysis tools such as GEPIA2, cBioPortal, TIMER2, Metascape, UALCAN, STRING, TISIDB, COSMIC investigate ZBTB9’s...
Background: The quest for dependable biomarkers to predict responses immune checkpoint inhibitors (ICIs) combined with chemotherapy in advanced non-small cell lung cancer remains unfulfilled. HOXC9, known its role oncogenesis and creating a suppressive tumor microenvironment (TME), shows promise enhancing predictive precision when included as TME biomarker. This study explores the significance of HOXC9 ICI plus efficacy adenocarcinoma (LUAD). Methods: Following bioinformatic findings, assays...
Poly ADP-ribose polymerase (PARP) inhibitor monotherapies are selectively effective in patients with pancreatic, breast, prostate, and ovarian cancers